Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 8 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Skarlos, Dimosthenis V  [Clear All Filters]
Journal Article
Koletsa, T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A. G., et al. (2014).  alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.. BMC Clin Pathol. 14, 28.
Fountzilas, G., Dafni U., Bobos M., Batistatou A., Kotoula V., Trihia H., et al. (2012).  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.. PLoS One. 7(6), e37946.
Kourea, H. P., Kotoula V., Koutras A., Alexopoulou Z., Papaspirou I., Skarlos D. V., et al. (2015).  Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study.. Histol Histopathol. 30(9), 1129-41.
Vassilakopoulou, M., Togun T., Dafni U., Cheng H., Bordeaux J., Neumeister V. M., et al. (2014).  In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.. PLoS One. 9(6), e99131.
Fountzilas, G., Kotoula V., Pectasides D., Kouvatseas G., Timotheadou E., Bobos M., et al. (2013).  Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.. PLoS One. 8(7), e69256.
Skarlos, D. V., Timotheadou E., Galani E., Samantas E., Grimani I., Lianos E., et al. (2009).  Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic C. Oncology. 77(2), 107-12.
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
Christodoulou, C., Kostopoulos I., Kalofonos H. P., Lianos E., Bobos M., Briasoulis E., et al. (2009).  Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.. Oncology. 76(4), 275-85.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές